Read Time:7 Second
Pfizer and BioNTech said Friday that a Phase 3 trial of their COVID-19-and-influenza combination vaccine candidate met one of its two objectives.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
